English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  Pazopanib, Cabozantinib, and Vandetanib in the Treatment of Progressive Medullary Thyroid Cancer with a Special Focus on the Adverse Effects on Hypertension

Milling, R. V., Grimm, D., Krueger, M., Grosse, J., Kopp, S., Bauer, J., et al. (2018). Pazopanib, Cabozantinib, and Vandetanib in the Treatment of Progressive Medullary Thyroid Cancer with a Special Focus on the Adverse Effects on Hypertension. International Journal of Molecular Sciences, 19(10): 3258. doi:10.3390/ijms19103258.

Item is

Basic

show hide
Genre: Journal Article

Files

show Files
hide Files
:
ijms-19-03258.pdf (Publisher version), 2MB
Name:
ijms-19-03258.pdf
Description:
(This article belongs to the Special Issue Cell and Molecular Biology of Thyroid Disorders)
Visibility:
Public
MIME-Type / Checksum:
application/pdf / [MD5]
Technical Metadata:
Copyright Date:
-
Copyright Info:
Open Access

Locators

show

Creators

show
hide
 Creators:
Milling, Rikke Vilsboll1, Author
Grimm, Daniela1, Author
Krueger, Marcus1, Author
Grosse, Jirka1, Author
Kopp, Sascha1, Author
Bauer, Johann2, Author              
Infanger, Manfred1, Author
Wehland, Markus1, Author
Affiliations:
1external, ou_persistent22              
2Scientific Service Groups, Max Planck Institute of Biochemistry, Max Planck Society, ou_1565170              

Content

show
hide
Free keywords: ENDOTHELIAL GROWTH-FACTOR; TYROSINE KINASE INHIBITORS; ANGIOGENESIS-INHIBITOR; BLOOD-PRESSURE; SIGNALING PATHWAY; SOLID TUMORS; CARCINOMA; MANAGEMENT; TRIAL; RETBiochemistry & Molecular Biology; Chemistry; medullary thyroid carcinoma; hypertension; VEGF; antiangiogenesis; tyrosine kinase inhibitors;
 Abstract: Medullary thyroid cancer (MTC) is a rare malignancy with a poor prognosis. First line therapy is surgery, which is the only curative method of the disease. However, in non-operable cases or with tumor progression and metastases, a systemic treatment is necessary. This form of cancer is often insensitive to conventional chemotherapy, but the use of tyrosine kinase inhibitors (TKIs), such as pazopanib, cabozantinib, and vandetanib, has shown promising results with an increase in progression-free survival and prolonged lifetime. Therefore, we focused on the pharmacological characteristics of TKIs, their mechanism of action, their application as a secondary treatment option for MTC, their efficacy as a cancer drug treatment, and reviewed the ongoing clinical trials. TKIs also act systemically causing various adverse events (AEs). One common AE of this treatment is hypertension, known to be associated with cardiovascular disease and can therefore potentially worsen the well-being of the treated patients. The available treatment strategies of drug-induced hypertension were discussed. The mechanism behind the development of hypertension is still unclear. Therefore, the treatment of this AE remains symptomatic. Thus, future studies are necessary to investigate the link between tumor growth inhibition and hypertension. In addition, optimized, individual treatment strategies should be implemented.

Details

show
hide
Language(s): eng - English
 Dates: 2018
 Publication Status: Published online
 Pages: 15
 Publishing info: -
 Table of Contents: -
 Rev. Type: -
 Identifiers: ISI: 000448951000413
DOI: 10.3390/ijms19103258
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: International Journal of Molecular Sciences
  Abbreviation : Int. J. Mol. Sci.
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: Basel, Switzerland : MDPI AG
Pages: - Volume / Issue: 19 (10) Sequence Number: 3258 Start / End Page: - Identifier: ISSN: 1422-0067
CoNE: https://pure.mpg.de/cone/journals/resource/1422-0067